ABL end of year summary information
February 12 2007 - 7:00AM
PR Newswire (US)
ALPINE, UT, Feb. 12 /PRNewswire-FirstCall/ -- American Biotech Labs
(ABL) is a private company in which Clifton Mining Company
(Clifton) is the largest individual shareholder. Annual Sales
------------ American Biotech Labs annual sales continued to grow
at more than 20%. All market sectors grew, with the fastest growth
occurring in sales of products to doctors and new volume purchase
contracts. Numerous new domestic and international contracts have
been signed, many within the last two months. The largest single
order in January 2007 was 130,000 bottles. New Products
------------ ABL is planning to release four (4) new products in
2007, three (3) of which are expected to be launched during the
second quarter. Two new gel products are awaiting approval and will
be released when approved. Both domestic and international clients
are already testing these new products. Filings have been made
internationally in the hope that new products can move quickly into
these markets. Military Special Operations
--------------------------- American Biotech Labs was invited to be
and has become an active member of the United States Special
Operations Medical Association. This association is dedicated to
the health and welfare of US Special Operations Medics and the
soldiers they care for. American Biotech Labs has been supplying
product to many of these medics who work in Iraq and to US Air
Marshals and fire fighters who are also part of the association.
Full Information Summary, Fact Sheet
------------------------------------ Said Keith Moeller, a Managing
Director, "2006 was an outstanding year for ABL but with the new
accounts the company has recently signed, we expect 2007 to be
substantially better. A great deal of time and money has been
expended in building an impressive intellectual property
foundation. ABL's reputation as a world leader in silver technology
continues to broaden, as documented by papers in prestigious
professional peer-reviewed journals." Management has completed a
year-end summary which will shortly be available on the American
Biotech Labs listing on Clifton's website home page at
http://www.cliftonmining.com/. If you click on the American Biotech
Labs button, the new summary will appear third on the list. New
Patent Information ---------------------- The unique SilverSol
Technology(TM) created and owned by ABL now has a patented
construction process, patented particle sizes and many patented end
uses. The patent covers a wide range of pathogens, including:
Anthrax and the bacteria that cause Bubonic plague; and Viruses
such as Hepatitis B and HIV; and, Parasitic diseases such as
Malaria. The patent also includes more common infectious agents an
ailments ranging from MRSA to TB, from UTIs to skin infections, ear
and eye infections, upper respiratory tract infections, STD's, and
others. The company is now working with military, government,
university, and medical organizations to study and develop
additional uses for the products and the technology. Information on
our most recent patent can be accessed through the patent link
button on the ABL website. The website also has a direct link to
the peer review antibiotic synergy study article. Clifton trades on
the U.S. OTC: (CFTN). Note: Any statements released by Clifton
Mining Company that are forward looking are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Editors and investors are cautioned that forward
looking statements invoke risk and uncertainties that may affect
the company's business prospects and performance. DATASOURCE:
Clifton Mining Company CONTACT: contact Dr. Ken Friedman,
President, at (303) 642-0659; Keith Moeller, Vice President, at
(801) 756-1414, or see our websites at
http://www.cliftonmining.com/ or at
http://www.americanbiotechlabs.com/
Copyright